FAMPYRA 10 MG

What is FAMPYRA?

FAMPYRA 10 MG contains FAMPRIDINE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02379910, held by ACORDA THERAPEUTICS IRELAND LIMITED, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 08-Jan-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is FAMPYRA used for?

FAMPYRA (fampridine) extended-release tablets are indicated for the symptomatic improvement of walking in adult patients with multiple sclerosis (MS) with walking disability (EDSS 3.5-7). The initial prescription should be for no more than 4 weeks, and assessment for improvement in walking should be carried out within that timeframe.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

How is it administered?

The maximum recommended dosage of FAMPYRA is one 10 mg tablet twice daily and should not be exceeded. Take doses approximately 12 hours apart. The recommended dose of FAMPYRA (fampridine) extended-release tablets is one 10 mg tablet twice daily. One 10 mg tablet should be taken in the morning and one 10 mg tablet should be taken in the evening. The doses should be taken 12 hours apart. Tablets should only be taken by swallowing whole with a glass of water. Doses should be taken without food. Patients should be advised to not divide, crush, dissolve, suck or chew the tablet because broken tablets can release too much of the drug at one time and increase the risk of seizure adverse events. Patients should also be advised not to take an extra dose if a dose is missed, due to the increased risk of seizure adverse events. The initial prescription for FAMPYRA should be for no more than 4 weeks of therapy as clinical benefits should generally be identified within 4 weeks after starting FAMPYRA. The assessment for evaluation of improvement should be conducted prior to starting treatment and again within 4 weeks. FAMPYRA should be discontinued if benefit is not reported by patient. Physicians should continue to actively review the benefit/risk of FAMPYRA for the individual patient, to ensure continued positive benefit/risk. In all cases, FAMPYRA should be discontinued if patients no longer report benefit, or if seizure occurs.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

Store FAMPYRA (fampridine) extended release tablets between 15 to 30° C in the original bottle to protect from light and moisture. Discard medicine after the expiry date shown on the packaging. Keep out of reach and sight of children.

How is it supplied?

Film-coated, white to off-white, biconvex, oval shaped, non-scored tablets with flat edge, debossed with ‘A10' on one side containing 10 mg fampridine. Bottles containing 14 tablets and a silica gel desiccant. Four bottles in a carton.

Contraindications

FAMPYRA (fampridine) extended-release tablets are contraindicated in: Patients who are hypersensitive to FAMPYRA or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. Hypersensitivity reactions, including anaphylaxis and angioedema, have been observed in patients treated with fampridine. Patients taking concurrent compounded 4-aminopyridine or other forms of fampridine. Patients with moderate or severe renal impairment (creatinine clearance <50mL/min). Patients with a prior history or current presentation of seizure. Patients taking medicinal products that are inhibitors of the renal Organic Cation Transporter 2 (OCT2), such as cimetidine and quinidine.

Warnings and precautions

FAMPYRA should be used under the supervision of a clinician experienced in the treatment of multiple sclerosis. Recommended dose should not be exceeded due to an increased risk of seizure. Treatment with fampridine increases seizure risk, with a dose-dependent increase observed in clinical studies at doses above 10 mg twice daily. Renal impairment and certain concomitant medications can increase fampridine plasma levels, increasing seizure risk. Hypersensitivity reactions, including anaphylaxis and angioedema, have been observed, sometimes after the first dose. Patients should be informed of serious allergic reaction symptoms and seek immediate emergency assistance if they occur. Concurrent treatment with other forms of 4-aminopyridine is contraindicated. FAMPYRA is a potassium channel blocker and should be administered with caution to patients with cardiovascular symptoms of rhythm and sinoatrial or atrioventricular conduction cardiac disorders. Dizziness or fatigue may occur, caution is advised for activities requiring mental alertness. A higher incidence of urinary tract infections (UTI) was reported with FAMPYRA (12%) than with placebo (8%). Exacerbation of Trigeminal Neuralgia has been reported in MS patients with a history of TN during postmarketing experience.

What can be used instead?

Other Canadian products sharing ATC code N07XX07 FAMPRIDINE. 3 of 4 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

Who else supplies FAMPRIDINE worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. FAMPRIDINE appears in 27 registered pack listings across 9 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.